Latest News for: dll3

Edit

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 ...

Nasdaq Globe Newswire 02 Jul 2026
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass ... 53 LR – Molecular Partners AG (SIX. MOLN; NASDAQ ... .
Edit

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 (Form 6-K) (Molecular Partners AG)

Public Technologies 02 Jul 2026
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712.
Edit

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 (Molecular Partners AG)

Public Technologies 02 Jul 2026
Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712 ... DLL3 is a highly ... "MP0712 is a Radio-DARPin designed to attack tumors by specifically leveraging DLL3 biology.
Edit

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 (Form 6-K) (Molecular Partners AG)

Public Technologies 01 Jun 2026
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 ... DLL3 is a highly relevant target for radiopharmaceutical therapy due ...
Edit

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing ...

Norfolk Daily News 31 May 2026
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to ... .
Edit

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, ...

The Galveston Daily News 11 May 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 11, 2026-- ....
Edit

Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences

Nasdaq Globe Newswire 04 May 2026
MOLN; NASDAQ ... .
Edit

Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences (Molecular Partners AG)

Public Technologies 04 May 2026
) PDF Version ... MOLN; NASDAQ ... Details of the events. ... May 6-7, Rockville, MD, USA. Title. Molecular characteristics of MP0712, a clinical stage ²¹²Pb-based Radio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung cancer (SCLC). Session.
  • 1

Article Search

tools
×
×
×
×